Sacha Inchi Plukenetia Volubilis.

Sacha inchi oil is dense in alpha-linolenic acid, a highly oxidisable polyunsaturated fat. Tocopherols interrupt the lipid peroxidation chain in the oil and in membranes, which is why they are the standard companion to any high-ALA oil.

Rosemary diterpenes such as carnosic acid are the usual oil-soluble antioxidant used to hold polyunsaturated oils stable during storage. They spare tocopherol by scavenging the first radicals formed.

Conversion of plant alpha-linolenic acid to DHA in humans is only a few percent, so a plant omega-3 raises ALA and EPA far more than DHA. A preformed DHA source fills the part of the omega-3 pool the plant oil cannot reach.

Delta-6 desaturase, the rate-setting enzyme that starts converting alpha-linolenic acid onward, depends on zinc status. Low zinc slows the step that turns plant omega-3 into longer chains.

Pyridoxine is reported as a cofactor for normal desaturase and elongase activity in the omega-3 elongation chain. That is the step turning alpha-linolenic acid into longer chain forms.

Linoleic acid and alpha-linolenic acid compete for the same delta-6 desaturase, and a high linoleic load crowds out omega-3 conversion. A formula carrying both should keep the omega-6 share modest for the plant omega-3 to convert.

Long chain omega-3 fats shift eicosanoid balance toward less platelet aggregation, and plant omega-3 pushes the same direction once converted. Stacking both raises the combined effect on normal clotting, which matters for anyone already on blood-thinning medicine.

Astaxanthin sits across the lipid bilayer and quenches radicals at both membrane surfaces, an arrangement that protects incorporated polyunsaturated fatty acids. It is used alongside omega-3 oils for that reason.

Alpha-tocopherol quenching a lipid radical becomes a tocopheroxyl radical, and ascorbate at the lipid-water interface reduces it back to tocopherol. In a highly unsaturated oil that recycling loop is what makes the tocopherol content go further. This is oxidative protection of the oil and of tocopherol status, not a claim about the fatty acids doing more work.

Tocotrienols are chain-breaking lipid antioxidants that sit in the same membrane and micelle compartments as the polyunsaturated fatty acids they protect. Adding them to a PUFA-rich oil follows the same logic as the tocopherols already present. Their distribution and turnover differ from alpha-tocopherol, so they are complementary rather than a substitute.

Alpha-linolenic acid from sacha inchi and linoleic acid compete for the same delta-6 desaturase, the rate-limiting step in both the omega-3 and the omega-6 elongation chains. Evening primrose oil is rich in linoleic acid and gamma-linolenic acid, so co-dosing loads the omega-6 side of that shared enzyme. Anyone taking sacha inchi for its ALA should know a large linoleic acid intake works against the conversion.

Flaxseed oil and sacha inchi oil are both plant sources whose predominant fatty acid is alpha-linolenic acid, so combining them adds ALA without adding anything new mechanistically. The same conversion bottleneck applies to both. Combining plant omega-3 sources raises intake of the precursor, which is a different thing from raising EPA or DHA status.

Conversion of alpha-linolenic acid to EPA in humans is limited and conversion onward to DHA more limited still, which is why a plant ALA source and a preformed long-chain omega-3 are not interchangeable. Supplying EPA directly bypasses the desaturase and elongase steps entirely. Pairing them covers both the precursor pool and the preformed fatty acid.

Free iron catalyses decomposition of lipid hydroperoxides through Fenton chemistry, which propagates peroxidation in a polyunsaturated oil. That is why iron and a PUFA oil are kept apart in a formulation and why an oil is co-packed with a tocopherol rather than with a mineral. In the gut the same reaction promotes lipid oxidation products from a fatty meal.

Copper is a redox-active transition metal that, like iron, accelerates lipid peroxidation of unsaturated fatty acids. Formulating a free copper salt into or beside an ALA-rich oil is an oxidative stability problem. The interaction is chemical stability, not a nutrient antagonism at the absorption step.

Lecithin is an amphiphilic phospholipid that emulsifies an oil into fine droplets, increasing the surface area available to pancreatic lipase and easing dispersion in a drink or powder. That is a physical formulation effect on the oil. It does not change the fatty acid composition or the conversion limits.

Medium-chain triglycerides are absorbed largely by the portal route and oxidised quickly, while the long-chain fatty acids in sacha inchi are packaged into chylomicrons through the lymphatic route. Blending the two gives a carrier oil with different handling from the active fraction. The medium-chain fraction is a vehicle and a rapid fuel, not an omega-3 source.

Vitamin D is fat soluble and its uptake depends on bile salt micelles, which form better in the presence of dietary fat. An oil taken at the same time supplies that fat. The enhancement is generic to dietary lipid; nothing about sacha inchi's fatty acid profile is specifically required.

Menaquinone-7 is lipophilic and is absorbed with dietary fat through the micellar route, which is why it is commonly supplied dissolved in an oil. Sacha inchi oil can serve as that carrier. This is a delivery relationship rather than a shared biochemical pathway.

Carotenoid absorption depends on the presence of fat to form mixed micelles, so a fat-free meal leaves much of a carotenoid dose unabsorbed. An ALA-rich oil provides that lipid. Beta-carotene is also itself a lipid-phase antioxidant, which is a second, weaker reason the two travel well together.

Lutein is a xanthophyll carotenoid whose absorption rises with co-ingested fat through the same micellar route. Formulating it in an oil is standard practice for that reason. The pairing addresses delivery, and says nothing about where the lutein ends up in tissue.

Ubiquinone is a large, poorly water-soluble lipophilic molecule and its absorption is limited without a lipid vehicle, which is why softgels present it dissolved in oil. Sacha inchi oil can act as that vehicle. Which oil is used is a formulation choice, and the enhancement comes from the lipid phase in general.

Curcuminoids are lipophilic and very poorly water soluble, so oral uptake improves when they are dispersed in a lipid or a phospholipid system. An oil co-dose supplies that phase. This is a solubility and delivery relationship and does not imply an added effect from either component.

Defatted sacha inchi meal is used as a plant protein, and its amino acid pattern differs from that of a dairy protein, so blending the two broadens the amino acid profile of the finished powder. That is standard protein blending logic, driven by measured amino acid composition rather than by any interaction. It also means the stored complete-protein claim should be read against the specific meal, not against the oil.